publication . Article . Other literature type . 2014

Clinical features in patients with long-lasting macrophagic myofasciitis

Muriel eRIGOLET; Jessie eAOUIZERATE; Jessie eAOUIZERATE; Maryline eCOUETTE; Nilusha eTHANGARAJAH; Nilusha eTHANGARAJAH; Mehdi eAOUN-SEBAITI; Romain Kroum GHERARDI; Romain Kroum GHERARDI; Romain Kroum GHERARDI; ...
Open Access English
  • Published: 28 Nov 2014 Journal: Frontiers in Neurology, volume 5 (eissn: 1664-2295, Copyright policy)
  • Publisher: Frontiers Media S.A.
Abstract
Macrophagic myofasciitis (MMF) is an emerging condition characterized by specific muscle lesions assessing abnormal long-term persistence of aluminum hydroxide within macrophages at the site of previous immunization. Affected patients usually are middle-aged adults, mainly presenting with diffuse arthromyalgias, chronic fatigue, and marked cognitive deficits, not related to pain, fatigue, or depression. Clinical features usually correspond to that observed in chronic fatigue syndrome/myalgic encephalomyelitis. Representative features of MMF-associated cognitive dysfunction include dysexecutive syndrome, visual memory impairment, and left ear extinction at dichot...
Subjects
free text keywords: Neuroscience, Review Article, aluminum, vaccines, myofasciitis, myalgias, chronic fatigue syndrome, mild cognitive impairment, neglected diseases, CCL2, Adjuvants, Immunologic, Depression, Neurology. Diseases of the nervous system, RC346-429, Cognition, Chronic pain, medicine.disease, medicine, Dementia, Mild cognitive impairment (MCI), business.industry, business, Visual memory, Macrophagic myofasciitis, Dysexecutive syndrome
Related Organizations
Funded by
EC| ENDOSTEM
Project
ENDOSTEM
Activation of vasculature associated stem cells and muscle stem cells for the repair and maintenance of muscle tissue
  • Funder: European Commission (EC)
  • Project Code: 241440
  • Funding stream: FP7 | SP1 | HEALTH
42 references, page 1 of 3

1 Gherardi RK Coquet M Chérin P Authier FJ Laforêt P Bélec L Macrop hagic myofasciitis: an emerging entity. Groupe d’Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l’Association Française contre les Myopathies (AFM). Lancet (1998) 352(9125):347–52.10.1016/S0140-6736(98)02326-5 9717921 [PubMed] [DOI]

2 Gherardi RK Coquet M Cherin P Belec L Moretto P Dreyfus PA Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain (2001) 124(Pt 9):1821–31.10.1093/brain/124.9.1821 11522584 [OpenAIRE] [PubMed] [DOI]

3 Authier FJ Sauvat S Christov C Chariot P Raisbeck G Poron MF AlOH3-adjuvanted vaccine-induced macrophagic myofasciitis in rats is influenced by the genetic background. Neuromuscul Disord (2006) 16(5):347–52.10.1016/j.nmd.2006.02.004 16616846 [OpenAIRE] [PubMed] [DOI]

4 Gherardi RK Authier FJ. Macrophagic myofasciitis: characterization and pathophysiology. Lupus (2012) 21(2):184–9.10.1177/0961203311429557 22235051 [OpenAIRE] [PubMed] [DOI]

5 Couette M Boisse MF Maison P Brugieres P Cesaro P Chevalier X Long-term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction. J Inorg Biochem (2009) 103(11):1571–8.10.1016/j.jinorgbio.2009.08.005 19748679 [OpenAIRE] [PubMed] [DOI]

6 Passeri E Villa C Couette M Itti E Brugieres P Cesaro P Long-term follow-up of cognitive dysfunction in patients with aluminum hydroxide-induced macrophagic myofasciitis (MMF). J Inorg Biochem (2011) 105(11):1457–63.10.1016/j.jinorgbio.2011.08.006 22099155 [OpenAIRE] [PubMed] [DOI]

7 Ragunathan-Thangarajah N Le Beller C Boutouyrie P Bassez G Gherardi RK Laurent S Distinctive clinical features in arthro-myalgic patients with and without aluminum hydroxyde-induced macrophagic myofasciitis: an exploratory study. J Inorg Biochem (2013) 128:262–6.10.1016/j.jinorgbio.2013.07.02 0 23921285 [OpenAIRE] [PubMed] [DOI]

8 Kissel JT Muscle biopsy in patients with myalgia: Still a painful decision. Neurology (2007) 68:170–1 10.1212/01.wnl.0000254503.91471.f5 17224566 [OpenAIRE] [PubMed] [DOI]

9 WHO Vaccine Safety Advisory Committee. Macrophagic myofasciitis and aluminum-containing vaccines. Wkly Epidemiol Rec (1999) 74:337–40.10613107 [PubMed]

10 Verdier F Burnett R Michelet-Habchi C Moretto P Fievet-Groyne F Sauzeat E Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the cynomolgus monkey. Vaccine (2005) 23(11):1359–67 10.101 6/j.vaccine.2004.09.012 15661384 [OpenAIRE] [PubMed] [DOI]

11 Khan Z Combadière C Authier FJ Itier V Lux F Exley C Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. BMC Med (2013) 11:99.10.1186/1741-7015-11-99 23557144 [OpenAIRE] [PubMed] [DOI]

12 Gherardi RK Authier FJ. Aluminum inclusion macrophagic myofasciitis: a recently identified condition. Immunol Allergy Clin North Am (2003) 23(4):699–712.10.1016/S0889-8561(03)00095-X 14753387 [PubMed] [DOI]

13 Caulfield MJ Shi L Wang S Wang B Tobery TW Mach H Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Hum Vaccin (2007) 3(4):139–45.10.4161/hv.3.4.4309 17581283 [OpenAIRE] [PubMed] [DOI]

14 Siegrist CA. Vaccine adjuvants and macrophagic myofasciitis. Bull Acad Natl Med. (2003) 187(8):1511–8. French.15146582 [PubMed]

15 Papo T Macrophagic myofasciitis: focal or systemic?Joint Bone Spine (2003) 70(4):242–5 10.1016/S1297-319X(03)00093-9 12951304 [OpenAIRE] [PubMed] [DOI]

42 references, page 1 of 3
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . Other literature type . 2014

Clinical features in patients with long-lasting macrophagic myofasciitis

Muriel eRIGOLET; Jessie eAOUIZERATE; Jessie eAOUIZERATE; Maryline eCOUETTE; Nilusha eTHANGARAJAH; Nilusha eTHANGARAJAH; Mehdi eAOUN-SEBAITI; Romain Kroum GHERARDI; Romain Kroum GHERARDI; Romain Kroum GHERARDI; ...